- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 657-27-2] L-Lysine hydrochloride
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-N0470 |
| Brand: | MCE |
| CAS: | 657-27-2 |
Overview
| MDL | MFCD00064564 |
|---|---|
| Molecular Weight | 182.65 |
| Molecular Formula | C6H15ClN2O2 |
| SMILES | N[C@@H](CCCCN)C(O)=O.[H]Cl |
3 Publications Citing Use of MCE
Summary
L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.
IC50 & Target
|
Microbial Metabolite
|
Human Endogenous Metabolite
|
In Vivo
L-lysine treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhances antioxidant activity. Pre- or post-treatment with L-lysine leads to significant decreases in the levels of malondialdehyde and nitric oxide, while significant enhancement is observed in the activities of antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) and glutathione [1] . L-lysine supplementation almost completely ameliorates vascular calcification. Dietary L-lysine strongly suppresses plasma intact parathyroid hormone in adenine rats and supports a proper bone-vascular axis. The conserved orientation of the femoral apatite in group Lys also evidences the bone-protective effects of L-lysine. Dietary L-lysine elevates plasma alanine, proline, arginine, and homoarginine but not lysine [2] . The dose-dependent delay in gastric emptying observed in rats is confirmed in humans with an increase in halftime of gastric emptying of 4 min/g L-lysine. Moreover, a dose-dependent increase in intestinal fluid accumulation is observed (0.4 mL/min/g L-lysine) [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01155609 | University of Washington|National Cancer Institute (NCI) |
Mucositis|Oral Complications of Chemotherapy|Oral Complications of Radiation Therapy|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Nasopharynx|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Nasopharynx|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Basal Cell Carcinoma of the Lip|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Lymphoepithelioma of the Oropharynx|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity
|
September 2010 | Not Applicable |
| NCT02756117 | Vanderbilt University|Vanderbilt University Medical Center |
Healthy|Pre-diabetic
|
May 2016 | Phase 1 |
| NCT01220388 | University Hospital, Rouen |
Male|Healthy Volunteers
|
October 2010 | Not Applicable |
| NCT00996242 | Göteborg University|Stanley Medical Research Institute |
Schizophrenia
|
September 2007 | Not Applicable |
| NCT00440804 | Farmacon |
Patent Ductus Arteriosus
|
December 2002 | Phase 3 |
| NCT05210504 | Vanderbilt University Medical Center |
Diabetes Mellitus, Type 2
|
March 9, 2022 | Phase 1 |
| NCT01579799 | University of Zurich |
Healthy
|
April 2012 | Not Applicable |
Appearance
Solid
Source
a genetically modified strain of Escherichia coli.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 547.50 mM ; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.4750 mL | 27.3748 mL | 54.7495 mL |
| 5 mM | 1.0950 mL | 5.4750 mL | 10.9499 mL |
| 10 mM | 0.5475 mL | 2.7375 mL | 5.4750 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (273.75 mM); Clear solution; Need ultrasonic
References
- [1] Al-Malki AL, et al. Suppression of acute pancreatitis by L-lysinein mice. BMC Complement Altern Med. 2015 Jun 23;15:193.
- [2] Baruffol C, et al. L-lysine dose dependently delays gastric emptying and increases intestinal fluid volume in humans and rats. Neurogastroenterol Motil. 2014 Jul;26(7):999-1009.
- [3] Shimomura A, et al. Dietary L-lysineprevents arterial calcification in adenine-induced uremic rats. J Am Soc Nephrol. 2014 Sep;25(9):1954-65.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.